HistoSonics has received regulatory approval from Taiwan’s Food and Drug Administration for its Edison Histotripsy System, a non-invasive cancer treatment device that uses focused ultrasound to destroy tumours without cutting, radiation, or thermal damage. The TFDA authorisation, announced on 18 May, marks a significant step in the company’s expansion into Asia and adds Taiwan to a growing list of markets where the technology is commercially available.

The approval follows a regulatory review process that the company said concluded with unanimous agreement from committee members. HistoSonics has already established a clinical presence in Taiwan through the National Taiwan University Hospital, the first institution in the country to install the system, where physicians treated patients under research protocols and achieved what the company describes as one of the fastest clinical adoption rates globally.

What histotripsy is and why it matters

Histotripsy is a non-thermal mechanical process that uses precisely focused sound waves to create controlled acoustic cavitation, essentially microscopic bubbles that expand and collapse with enough force to destroy targeted tissue at the subcellular level. Unlike thermal ablation techniques that burn tumours, or radiation therapy that damages DNA, histotripsy mechanically liquefies tissue without heating the surrounding area. The destroyed tissue is then absorbed and cleared naturally by the body’s immune system.

The Edison system, which HistoSonics developed over more than two decades from research originating at the University of Michigan, received its initial US FDA De Novo authorisation in October 2023 for the non-invasive destruction of liver tumours, including unresectable liver tumours. That clearance made Edison the first and only histotripsy platform available in the United States. One-year clinical data from the pivotal trial suggest a 90 per cent tumour control rate, a figure that has drawn attention from oncologists treating patients who are not candidates for surgery.

The 💜 of EU tech

The latest rumblings from the EU tech scene, a story from our wise ol’ founder Boris, and some questionable AI art. It’s free, every week, in your inbox. Sign up now!

The technology sits in a rapidly expanding space where AI and advanced technology are reshaping healthcare delivery, though histotripsy is notable for being a physical intervention with measurable clinical outcomes rather than a software-based diagnostic tool. Its mechanism of action, using sound rather than incisions or radiation, means patients can potentially be treated as outpatients with minimal recovery time, a proposition that appeals to healthcare systems under pressure to reduce costs and hospital stays.

The company behind the technology

HistoSonics is not a scrappy startup. Founded in 2009 in Ann Arbor, Michigan, the company was valued at $2.25 billion in August 2025 when a consortium of investors including K5 Global, Bezos Expeditions, and Wellington Management acquired a majority stake. That transaction, which installed CEO Mike Blue as chairman of the board, was followed two months later by an oversubscribed $250 million growth financing round led by K5 Global with participation from Thiel Bio and Founders Fund. The total capital raised exceeds $560 million across 11 funding rounds.

The investor roster reads like a who’s who of technology-adjacent capital. Jeff Bezos’s investment vehicle and Peter Thiel’s biotech fund are not typical medtech backers, and their involvement signals a thesis that histotripsy represents a platform technology with applications well beyond its current liver indication, one that could eventually address kidney, pancreatic, and prostate tumours. Samsung’s acquisition of French AI ultrasound startup Sonio for €86 million illustrates the broader trend of major technology and healthcare companies investing in ultrasound-based platforms, though HistoSonics’ therapeutic application is far more ambitious than diagnostic imaging.

Taiwan and the Asia expansion

The TFDA approval is strategically significant for two reasons. First, Taiwan has a sophisticated healthcare system with strong institutional research capacity, making it an ideal market for generating the clinical data that regulatory bodies in other Asian countries will want to see. Second, the approval comes at a moment when HistoSonics is pursuing multiple regulatory and clinical milestones simultaneously.

Taipei Veterans General Hospital has already acquired an Edison system, with its director comparing the technology to a legendary weapon and announcing plans to offer free treatment to 50 patients with liver cancer or liver metastases within six months as part of clinical trials. The acquisition was reportedly inspired by Hong Kong billionaire Li Ka-shing’s donation of a histotripsy system to the University of Hong Kong in 2024, a detail that illustrates how philanthropic deployment can accelerate commercial adoption in new markets.

HistoSonics has said it plans to expand collaborations with physicians and institutions across Taiwan and the broader Asia-Pacific region, with a focus on producing clinical data, broadening indications through research, and developing training programmes for physicians. The company has treated more than 2,000 patients at over 50 active centres worldwide, according to its most recent disclosures.

The pipeline beyond liver

One week before the Taiwan approval, on 11 May, HistoSonics submitted a De Novo application to the US FDA seeking authorisation to expand the Edison system’s use to kidney tumours. The submission is supported by the HOPE4KIDNEY pivotal trial, which enrolled 67 patients and completed enrolment in June 2025. CEO Mike Blue described the submission as “an important milestone in expanding histotripsy beyond the liver and into the kidney, an area where patients and physicians are seeking organ-preserving and nephron-sparing alternatives.”

The kidney indication is clinically significant. Small renal masses are increasingly detected incidentally through imaging, and many patients, particularly elderly or comorbid individuals, are poor candidates for surgery. A non-invasive, non-thermal alternative that preserves kidney function could address a genuine gap in the treatment landscape. Beyond kidney, HistoSonics is evaluating the technology for pancreatic and prostate applications, though those programmes are at earlier stages.

The broader context is a healthcare sector increasingly shaped by technology, from AI-powered diagnostic tools that are changing how clinicians work to venture capital flowing into biotech and life sciences at unprecedented rates. HistoSonics occupies an unusual position in this landscape: it is a hardware company in a software-obsessed investment environment, selling a physical device that does something no software can do. The TFDA approval in Taiwan is one more data point suggesting that the market for non-invasive tumour destruction is real, growing, and increasingly global.